AstraZeneca study highlights patients most likely to benefit from asthma therapy

AstraZeneca has announced new clinical trial data that can help to predict which asthma patients would respond best to treatment with its drug benralizumab.

A subgroup analysis of the SIROCCO and CALIMA phase III trials have confirmed benralizumab's strong efficacy performance, while also identifying key factors for selecting patients with severe, uncontrolled asthma who would benefit most from this therapy.

It was indicated that patients with more frequent prior exacerbations and/or greater baseline blood eosinophil counts were more likely to see an enhanced treatment effect, as well as those on oral corticosteroids and with nasal polyposis.

These findings could make it easier for clinicians to develop a personalised treatment approach to guide more precise selection of benralizumab-responsive patients and help achieve maximum clinical benefit.

Colin Reisner, head of respiratory global medicines development at AstraZeneca, said: "This new analysis of SIROCCO and CALIMA builds on robust clinical evidence supporting benralizumab for patients with severe, uncontrolled asthma, including more recent data from the phase III ZONDA trial."

Benralizumab is currently under regulatory review in the EU, with a decision expected in the first half of 2018.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.